The End of the Large-Batch Playbook

Biomanufacturing is moving away from standardized, large-batch production toward systems capable of handling molecular diversity and individualized medicine. At the Danaher Bioprocessing Summit, industry leaders discussed the transition from scientific breakthroughs to patient impact, signaling that competitive advantage now depends on process intelligence rather than simple capacity expansion.

The traditional manufacturing model was built for standardized therapies. This approach fails when applied to the next generation of medicines, such as cell and gene therapies, targeted biologics, and N-of-1 treatments. As these therapies increase in complexity, the industry must shift toward smaller, parallel, and distributed systems. Success requires process designs that are data-driven and purpose-built from the start, rather than adapted from old methods.

This shift necessitates a fundamental change in how companies approach development. Manufacturing can no longer be treated as a downstream problem; it must be integrated into the scientific conversation from day one.

The integration of automation, AI, and high-throughput experimentation is addressing the primary barrier to personalized medicine: the inability to manufacture patient-specific therapies with the same efficiency as traditional mass-produced drugs. These tools enable a move toward small-batch and patient-specific manufacturing while improving regulatory consistency and access.

Key themes from the summit include:

• AI-driven bioprocess development and manufacturing
• Intensified and continuous bioprocessing
• Digitalization and connected data ecosystems
• Improving productivity and reducing cost of goods
• Cell and gene therapy manufacturing challenges
• Scaling production of high-demand biologics, including GLP-1 therapies
• Advanced analytics and process control
• Sustainability in biomanufacturing

The industry is moving from a focus on volume to a focus on speed and precision. For manufacturers, the challenge is no longer just about building more factories, but about mastering the data and automation required to manage complexity at scale.

How will your manufacturing strategy adapt when the unit of production shifts from a million doses to a single patient?